Apollo Hospitals vs Indian Hospital Chain Peers - Valuation & Quality Comparison 2026
- Comparison Date: September 28, 2026
- Companies: Apollo Hospitals Enterprise (NSE:APOLLOHOSP), Fortis Healthcare (NSE:FORTIS), Max Healthcare Institute (NSE:MAXHEALTH), Narayana Hrudayalaya (NSE:NH), Global Health / Medanta (NSE:MEDANTA), Krishna Institute of Medical Sciences (NSE:KIMS), Rainbow Children's Medicare (NSE:RAINBOW), Aster DM Quality Care (NSE:ASTERDM)
- Sector: Private Hospital Chains — India (see Sector Overview for structural trends)
Summary
Apollo Hospitals is the largest, most diversified, and highest-quality-adjusted-value large-cap in the group, but it is not the cheapest stock in the sector on pure valuation — Narayana Hrudayalaya and Rainbow Children's Medicare both screen cheaper relative to their return profiles. At the other extreme, Krishna Institute of Medical Sciences (KIMS) and the newly merged Aster DM Quality Care trade at valuations (PE 154x and 181x respectively) that are disconnected from their current ROE (11.3% each) — the sector's clearest red flags.
Market Capitalization & Scale
| Company | Ticker | Mkt Cap (Rs. Cr) | CMP (Rs.) | Beds / Facilities |
|---|---|---|---|---|
| Apollo Hospitals | APOLLOHOSP | 1,27,380 | 8,860 | 10,200 beds / 73 facilities |
| Max Healthcare | MAXHEALTH | 97,341 | 1,000 | Targeting 10,000 beds by FY30 (~2x current base per company guidance; current count not independently verified) |
| Aster DM Quality Care | ASTERDM | 65,157 | 747 | 10,600+ beds post-merger (targeting 13,300 by FY27) |
| Fortis Healthcare | FORTIS | 62,925 | 831 | Data not available (not independently verified this session) |
| Global Health (Medanta) | MEDANTA | 38,543 | 1,433 | 3,435 beds / 6 hospitals |
| Narayana Hrudayalaya | NH | 37,195 | 1,820 | 5,554 beds / 42 facilities |
| KIMS (Krishna Institute) | KIMS | 32,196 | 766 | ~8,000+ beds (Telangana, Andhra Pradesh, Maharashtra and other states) |
| Rainbow Children's Medicare | RAINBOW | 13,949 | 1,373 | 2,565 beds / 24 hospitals + 5 clinics (pediatric/women's health niche) |
Naming caution: "KIMS" in this table refers to the separately listed Krishna Institute of Medical Sciences Ltd (Hyderabad/Telangana). This is a different entity from "KIMSHEALTH" (Kerala), which merged into Aster DM Quality Care in July 2026 — the similar initials are a coincidence, not a corporate relationship.
Fundamental Comparison
| Metric | Apollo | Fortis | Max HC | Narayana H | Medanta | KIMS | Rainbow | Aster DM QC |
|---|---|---|---|---|---|---|---|---|
| PE Ratio | 60.6 | 59.0 | 65.0 | 43.2 | 67.3 | 154.0 | 48.7 | 181.0 |
| P/B Ratio | 13.4 | 6.34 | 9.06 | 8.20 | 9.73 | 13.6 | 8.46 | 9.22 |
| ROE % | 21.2 | 11.2 | 14.7 | 20.5 | 15.2 | 11.3 | 15.9 | 11.3 |
| ROCE % | 17.4 | 13.4 | 14.7 | 15.5 | 17.4 | 9.50 | 17.4 | 11.6 |
| OPM % | 15% | 23% | 27% | ~20% | 21% | 21% | 32% | 19% |
| Revenue Growth YoY | 16% | 18% | 22% | 44%* | 20% | 31%** | 12% | 16%** |
| Debt/Equity | 0.32x | Data not available | Data not available | ~1.29x*** | Low (Rs. 1,190 Cr borrowings) | Rising — flag | Data not available | Data not available |
| Promoter % | 28.02% | 31.17% | 23.71% | 63.27% | 33.00% | 32.49% | 49.84% | 53.72% |
| Promoter Pledge % | 2.49% | Data not available | Data not available | Data not available | Data not available | Data not available | Data not available | Data not available |
| FII % | 41.49% | 25.20% | 41.78% | 9.40% | 9.46% | 14.75% | 16.03% | 10.32% |
| DII % | 23.72% | 32.23% | 29.95% | 9.05% | 16.89% | 34.42% | 22.56% | 16.48% |
| Dividend Yield | 0.23% | 0.12% | 0.20% | 0.25% | 0.03% | 0.00% | 0.25% | 0.40% |
*Narayana Hrudayalaya's 44% YoY growth is well above sector norms — treat as reported, not adjusted for possible new-facility base effects.
**KIMS and Aster DM Quality Care growth figures are TTM basis; not independently verified against a clean FY26-vs-FY25 comparison this session.
***Narayana Hrudayalaya D/E carried from its last verified figure (June 2026); not re-fetched this session.
Pledge data note: Only Apollo Hospitals' promoter pledge (2.49%) was confirmed from available sources this session. All other companies' pledge percentages were not disclosed in the Screener.in overview pulled — treat as unverified rather than assuming zero, and check NSE shareholding-pattern filings directly before relying on this for a real investment decision.
Quality-Adjusted Valuation (PE ÷ ROE — Lower Is Cheaper)
| Rank | Company | PE | ROE % | PE/ROE | Read |
|---|---|---|---|---|---|
| 1 (cheapest) | Narayana Hrudayalaya | 43.2 | 20.5 | 2.11 | Cheapest quality-adjusted valuation in the sector, but carries the highest disclosed leverage (D/E ~1.29x) among peers with a comparable figure |
| 2 | Apollo Hospitals | 60.6 | 21.2 | 2.86 | Best combination of scale, brand moat, and quality-adjusted valuation among the large-caps |
| 3 | Rainbow Children's Medicare | 48.7 | 15.9 | 3.06 | Best-in-class OPM (32%) and a defensible pediatric/women's-health niche at a reasonable multiple, but growth (12% YoY) trails peers |
| 4 | Max Healthcare | 65.0 | 14.7 | 4.42 | Largest scale and best margins (27% OPM) among large-caps, but valuation is not cheap for the return profile |
| 5 | Global Health (Medanta) | 67.3 | 15.2 | 4.43 | Premium North-India brand with strong growth, valuation broadly in line with Max |
| 6 | Fortis Healthcare | 59.0 | 11.2 | 5.27 | Similar absolute PE to Apollo but with the weakest ROE among large-caps — worse quality-adjusted value |
| 7 | KIMS (Krishna Institute) | 154.0 | 11.3 | 13.63 | Major red flag — valuation priced for growth well beyond current 11.3% ROE, alongside rising debt |
| 8 (richest) | Aster DM Quality Care | 181.0 | 11.3 | 16.02 | The sector's richest valuation by a wide margin, on top of fresh (July 2026) four-way merger integration risk |
Red Flags & Standouts
Biggest valuation/quality red flags: Aster DM Quality Care (PE 181x against 11.3% ROE, plus unproven post-merger integration) and KIMS/Krishna Institute (PE 154x against 11.3% ROE, plus rising leverage funding an aggressive M&A pace) are both priced well ahead of their current fundamentals. Neither shows a governance red flag (no confirmed pledge issue) — the concern is purely valuation-versus-returns.
Cheapest quality-adjusted standout: Narayana Hrudayalaya (PE/ROE 2.11), though its higher leverage (D/E ~1.29x, last verified) is the offsetting risk that likely explains part of the valuation discount.
Best margin profile: Rainbow Children's Medicare (32% OPM) and Max Healthcare (27% OPM) — both ahead of Apollo's pharmacy-diluted 15% consolidated OPM (Apollo's hospital-only segment margin is separately estimated at 20-22%; see the Apollo Hospitals comprehensive analysis for that adjustment).
Highest promoter conviction: Narayana Hrudayalaya (63.27%) and Aster DM Quality Care (53.72%) have the strongest promoter holdings in the set; Apollo (28.02%) and Max Healthcare (23.71%) have the lowest, reflecting decades of dilution to fund hospital expansion — not necessarily a governance concern on its own, but worth monitoring alongside FII/DII conviction (both strong for Apollo and Max).
Recommendation Ranking
- Apollo Hospitals (NSE:APOLLOHOSP) — Highest-quality large-cap franchise: unmatched scale (10,200 beds), integrated pharmacy + digital health moat, second-best quality-adjusted valuation. See the dedicated comprehensive analysis (Score 6.7/10, Buy on Dips) for the full case.
- Narayana Hrudayalaya (NSE:NH) — Cheapest quality-adjusted valuation in the sector (PE/ROE 2.11) with a strong 20.5% ROE, but higher leverage than large-cap peers is the key risk to monitor.
- Rainbow Children's Medicare (NSE:RAINBOW) — Best-in-class margins and a defensible pediatric-care niche at a reasonable multiple; slower revenue growth (12%) is the main drag versus faster-growing peers.
- Max Healthcare (NSE:MAXHEALTH) — Largest hospital chain by market cap with the best margins among large-caps (27% OPM) and a credible FY30 bed-doubling plan, but valuation offers little margin of safety.
- Global Health / Medanta (NSE:MEDANTA) — Premium North-India super-specialty brand with strong growth (80.7% 5-year profit CAGR) and an active expansion pipeline (Ghaziabad land allotment), valued broadly in line with Max Healthcare.
- Fortis Healthcare (NSE:FORTIS) — Improving via new hospital agreements (Ashok Vihar, Delhi), but the weakest ROE (11.2%) among large-caps at a PE similar to Apollo makes it the weakest quality-adjusted large-cap pick.
- KIMS / Krishna Institute of Medical Sciences (NSE:KIMS) — Avoid new entry: PE 154x against 11.3% ROE and rising debt funding an aggressive expansion/M&A pace is not defensible at current levels.
- Aster DM Quality Care (NSE:ASTERDM) — Avoid new entry: the sector's richest valuation (PE 181x) combined with fresh, unproven four-way merger integration risk (Aster + CARE Hospitals + KIMSHEALTH Kerala + Evercare, completed July 2026) makes this the highest-risk name in the group on a risk-adjusted basis.
Related Analyses
- Indian Hospital Chains Sector Overview
- Apollo Hospitals Enterprise - Comprehensive Analysis
- Indian Pharmaceutical Sector Overview (adjacent sector — drug manufacturers, not hospital operators)
Disclaimer
This analysis is for educational and informational purposes only and does not constitute investment advice. Fundamental scores, rankings, and recommendations are LLM-generated estimates based on publicly available data as of the stated access date and should not be relied upon as a substitute for independent due diligence or professional financial advice. Several data points (debt/equity, promoter pledge for non-Apollo companies, some bed counts) were not available or independently verified this session and are marked accordingly — conduct your own research and consult a qualified financial advisor before making investment decisions.
Data Sources
- Screener.in — Consolidated financials, ratios, shareholding for all 8 companies (Accessed: 2026-09-28)
- WebSearch (GuruFocus, MarketScreener, Digital Health News, Tradebrains, Healthcare MEA, ValueResearchOnline) — Ticker verification (Global Health/Medanta), bed capacity figures, Aster-Quality Care merger details (Accessed: 2026-09-28)
Data Timestamp: September 28, 2026, IST